LIN vs STRO
Linde plc Ordinary Shares (LIN) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported LIN revenue for 2025-12-31 was $33.99B. Net income was $6.90B. Revenue was up 3.0% from 2024-12-31 to 2025-12-31. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
LIN currently screens at market cap $223.87B and trailing P/E 34.5. STRO currently screens at market cap $470.8M.
Not investment advice. Open the LIN and STRO stock pages for the full models.
Not investment advice.